Prenatal exposure to misoprostol and vascular disruption defects: A case-control study

Abstract

Prenatal exposure to misoprostol has been associated with Moebius and limb defects. Vascular disruption has been proposed as the mechanism for these teratogenic effects. The present study is a multicenter, case-control study that was designed to compare the frequency of prenatal misoprostol use between mothers of Brazilian children diagnosed with vascular disruption defects and matched control mothers of children diagnosed with other types of defects. A total of 93 cases and 279 controls were recruited in eight participating centers. Prenatal exposure was identified in 32 infants diagnosed with vascular disruption defects (34.4%) compared with only 12 (4.3%) in the control group (P<0.0000001). Our data suggest that prenatal exposure to misoprostol is associated to the occurrence of vascular disruption defects in the newborns.

Exposure to misoprostol and hormones during pregnancy and risk of congenital anomalies

“…In order to avoid potential biases due to selection of healthy controls, Vargas et al 30 compared 93 newborns with various vascular disruption anomalies and 279 controls with minor or chromosomal anomalies, among other birth defects not caused by vascular disruption. Prenatal exposure to misoprostol was identified in 32 cases (34.4%) and 12 controls (4.3%) (OR = 11.67; 95%CI: 5.68-23.97).…”

Embriopatías Asociadas Al Uso De Misoprostol

“…De acuerdo a una encuesta realizada en 7 hospitales de Río de Janeiro, aproximadamente el 57% de las mujeres que ingresaban por aborto incompleto admitieron haber usado misoprostol como método abortivo (8,9). Pese a ser un fárma-co bastante efectivo en terminar un embarazo, un 10-15% de las pacientes continúan con la gesta- (10,(17)(18)(19)(20)(21)(22)(23)(24). Se ha estudiado el mecanismo por el cual misoprostol pudiese causar el SM.…”

Pharmacological safety during pregnancy: the principles of teratogenesis and teratogenicity of drugs

“…Эти тератогены могут уменьшать плацентарный или фетальный кровоток, влиять на развитие кровеносных сосудов, изменяя таким образом структуру и/или анатомию сосудистого русла. В ряде эпидемиологических исследований выявлены вазоактивные препараты, ассоциированные с сосудисты-ми нарушениями: мизопростол [55,56], ацетилсалицило-вая кислота [57,58], эрготамин [59,60] и псевдоэфедрин [58,61]. Однако, все препараты с сосудосуживающим или сосудорасширяющим эффектом могут стать причиной врожденных аномалий вследствие сосудистых наруше-ний.…”